Sanofi (SNY) Accounts Payables (2009 - 2025)

Sanofi has disclosed Accounts Payables across 17 years of filings, most recently posting $8.6 billion for Q4 2025.

• Accounts Payables for Q4 2025 came in at $8.6 billion, up 6.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.6 billion (up 6.19% YoY), and the FY2025 annual result was $8.6 billion, up 6.19% from the prior year.
• Accounts Payables came in at $8.6 billion for Q4 2025 at Sanofi, up from $8.0 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.6 billion in Q4 2025 to a low of $6.5 billion in Q2 2021.
• The 5-year median for Accounts Payables is $7.9 billion (2023), against an average of $7.6 billion.
• Across the five-year window, Accounts Payables gained 19.42% in 2021 and slipped 1.68% in 2022, its largest moves.
• Sanofi's Accounts Payables stood at $7.1 billion in 2021, then slipped by 1.68% to $7.0 billion in 2022, then gained by 13.43% to $7.9 billion in 2023, then rose by 2.34% to $8.1 billion in 2024, then climbed by 6.19% to $8.6 billion in 2025.
• The last three Accounts Payables figures came in at $8.6 billion (Q4 2025), $8.0 billion (Q2 2025), and $8.1 billion (Q4 2024), per Business Quant data.